During the corresponding time, Ani Pharmaceuticals Inc recorded a revenue increase by 25.87 % year on year, sequentially revenue grew by 12.04 %. While revenue at the Ani Pharmaceuticals Inc's corporate clients
Ani Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company serves customers in the healthcare sector, focusing on the United Kingdom and European Union markets. Its product ILUVIEN, containing fluocinolone acetonide, has received marketing authorization in these regions. The marketing authorization holder transitioned from Campharm Limited to Alimera Sciences Limited. ILUVIEN was approved through various EU regulatory procedures involving Member States including Austria, France, Germany, Italy, Portugal, Spain, Belgium, Czech Republic, Denmark, Finland, Luxembourg, Norway, Poland, Republic of Ireland, Sweden, and the Netherlands. Following the UK's exit from the EU, the Republic of Ireland serves as the Reference Member State. The company operates under regulatory frameworks such as the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA), adhering to post-authorization Risk Management Plans to monitor safety and manage risks associated with medicinal products.
ANI Pharmaceuticals Receives FDA Approval for Purified Cortrophin Gel Prefilled Syringe Amidst Strong Revenue GrowthIn a significant stride within the biopharmaceutical landscape, ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) recently announced the approval of its new presentation of Purified Cortrophin Gel (repository corticotropin injection USP) in a prefilled syringe format by the U.S. Food and Drug Administration (FDA). This innovative delivery system is a testament to ANI s commitment to innovation and patient-centric solutions, marking a pivotal moment in the administration of this important medication. Expanding Access to Purified Cortrophin Gel The new prefilled syringe for Purified Cortrophin Gel will...
ANI Pharmaceuticals Introduces L-Glutamine Oral Powder, Expanding its Generic Drug Portfolio while Achieving Impressive Revenue GrowthIn a recent breakthrough, ANI Pharmaceuticals, Inc. (ANI or the Company) has confirmed the approval and subsequent launch of L-Glutamine Oral Powder, following the green light from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA). This new product by ANI Pharmaceuticals marks an exciting addition to their comprehensive lineup of generic drugs, and is set to create a significant impact in the pharmaceutical industry.L-Glutamine Oral Powder, ANI s rendition of the reference listed drug (RLD) Endari, is primed to revolutionize the treatm...
The launch of Baclofen Oral Suspension marks a momentous milestone for ANI Pharmaceuticals. This generic version of Fleqsuvy offers patients an affordable yet equally effective treatment option for muscle spasms and multiple sclerosis. By providing access to Baclofen Oral Suspension, ANI Pharmaceuticals is contributing to improved patient outcomes and accessibility to necessary medications.Fleqsuvy, the reference listed drug (RLD), has been widely regarded as an effective solution for muscle-related disorders. However, its high cost has hindered accessibility for many patients. The introduction of Baclofen Oral Suspension by ANI Pharmaceuticals aims to bridge this affordability gap and ensure that patients c...
ANI Pharmaceuticals, a leading pharmaceutical company, has made yet another groundbreaking achievement with the successful launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg. This remarkable development not only brings a new medication option to patients but also showcases the company s commitment to innovation and expansion in the pharmaceutical industry.Pentoxifylline, an active ingredient in the newly released tablet, is commonly prescribed to alleviate symptoms associated with reduced blood circulation. With ANI Pharmaceuticals Extended-Release tablets, patients can now benefit from a sustained release of the drug, allowing for prolonged therapeutic effects and improved convenience in dos...
Ani Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company serves customers in the healthcare sector, focusing on the United Kingdom and European Union markets. Its product ILUVIEN, containing fluocinolone acetonide, has received marketing authorization in these regions. The marketing authorization holder transitioned from Campharm Limited to Alimera Sciences Limited. ILUVIEN was approved through various EU regulatory procedures involving Member States including Austria, France, Germany, Italy, Portugal, Spain, Belgium, Czech Republic, Denmark, Finland, Luxembourg, Norway, Poland, Republic of Ireland, Sweden, and the Netherlands. Following the UK's exit from the EU, the Republic of Ireland serves as the Reference Member State. The company operates under regulatory frameworks such as the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA), adhering to post-authorization Risk Management Plans to monitor safety and manage risks associated with medicinal products.
Sources:
Ani Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ani Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Ani Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
72.26 %